+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Axial Spondyloarthritis Market, By Commercialized Therapies, By Potential Pipeline Products ,By Indication, By Region: Trend Analysis, Competitive Market Share & Forecast, 2018-2028.

  • PDF Icon

    Report

  • 240 Pages
  • August 2022
  • Region: Global
  • Blueweave Consulting & Research Pvt Ltd
  • ID: 5647182

Global Axial Spondyloarthritis Market to Reach USD 4.95 Billion by 2028


The growth of the global axial spondyloarthritis market can be ascribed to the rise in research and development activities by the major market players for developing novel therapeutics for the treatment of axial spondyloarthritis market. Moreover, the increasing public awareness of the disease is likely to propel the market growth over the forecast period.

The global Axial Spondyloarthritis Market was worth USD 1,910.7 million in 2021, and it is further projected to reach USD 4,953.6 million by 2028, at a CAGR of 14.8% during 2022-2028 (forecast period). Solutions for Patient Engagement With the increasing implementation of digital technologies across the healthcare industry, market size is expected to expand significantly over the forecast period of 2022 to 2028. The growth of the global axial spondyloarthritis market can be ascribed to the rise in research and development activities by the major market players for developing novel therapeutics for the treatment of the axial spondyloarthritis market. Moreover, the increasing public awareness of the disease is likely to propel market growth over the forecast period.

The rise in Research and Development coupled with Increasing Public Awareness of the Disease is Likely to Propel the Market Growth


The rising focus of numerous biotechnological companies on R&D activities is likely to propel the axial spondyloarthritis (axSpA) market growth. Major market players are engaged in developing novel therapeutics, including anti-janus kinase therapy, anti-interleukin therapy, and anti-tumor necrosis factor therapy, which is substantially impacting the growth of the axial spondyloarthritis market. Moreover, the introduction of tumor necrosis factor inhibitors and interleukin 17 inhibitors has started a new era of drug therapy. Similarly, the increment in the number of approved biosimilars is also likely to boost the growth of the Axial Spondyloarthritis (axSpA) market over the forecast period.

On the other hand, axial spondyloarthritis is growing, particularly among the elderly population. As a result, the public is becoming more aware of the disease. Public awareness includes symptoms of the diseases, prevention of diseases, and early diagnosis of the diseases. Moreover, the camps conducted by the government about healthcare create awareness in public. Due to increased awareness in public, the high demand for drugs used in disease will also contribute to the growth of the global axial spondyloarthritis market. The increasing prevalence of Axial Spondyloarthritis (axSpA) is expected to drive the growth of the market.

Global Axial Spondyloarthritis Market- By Potential Pipeline Products


On the basis of potential pipeline products, the global axial spondyloarthritis market has been segmented into anti-janus kinase therapy (JAK), anti-interleukin (IL)-17 therapy, and others. Amidst the segmentation, the anti-interleukin 17 segments dominated the global axial spondyloarthritis market in the potential pipeline products category in 2021. Anti-Granulocyte/macrophage colony-stimulating factor (GM-CSF) and anti-phosphodiesterase 4 (PDE4) therapy are two other options. Owing to a growing corpus of solid long-term evidence, Cosentyx (secukinumab), Novartis' first-to-market IL-17A inhibitor, is projected to observe significant acceptance and expansion. Likewise, the growing adoption of Eli Lilly's Taltz (ixekizumab), an IL-17A inhibitor, is expected to contribute to market growth during the forecast period.

Asia-Pacific Region Is Expected to Grow with The Highest CAGR In the Global Axial Spondyloarthritis Market.

In terms of regional analysis, the global axial Spondyloarthritis market has been classified into North America, Europe, the Asia-Pacific, Latin America and the Middle East, and Africa. Amidst the segmentation, the Asia-Pacific region is expected to be the largest growing market in the global axial Spondyloarthritis market. This can be ascribed to the large population and the growing geriatric population in the region. According to UNFPA, the Asia and the Pacific region accounts for 60% of the world’s population, housing around 4.3 billion people, and comprises the world’s most populous countries, China and India. Moreover, the improving healthcare infrastructure in the countries of the region is driving the axial spondyloarthritis market in the region over the forecast period.

Impact Of COVID-19 On the Global Axial Spondyloarthritis Market




The COVID-19 pandemic has significantly burdened novel axial spondyloarthritis treatment research and development. Companies working in the field of axial spondyloarthritis had to change their focus to COVID-19 treatment pharmaceutical research and development in order to aid governments and communities throughout the world. This resulted in a delay in the distribution of new treatments and products. The sudden outbreak of the pandemic disrupted the manufacture and supply of axial spondyloarthritis medications. Governments worldwide implemented lockdowns, which severely hindered commercial operations due to the transit ban. This condition lasted until the second quarter of 2020, substantially impacting the global axial spondyloarthritis market and resulting in a drop in therapeutic commercialization revenue. Patients with axial spondyloarthritis have had limited access to new treatments as a result of these instances. Nevertheless, with the improving market circumstances in the post-covid era, the growth of the axial Spondyloarthritis market is likely to recover during the forecast period.

Competitive Landscape


The global axial spondyloarthritis Market is characterized by many local, regional, and global vendors. The key players operating in the global axial spondyloarthritis market are AbbVie Inc, Amgen Inc, Bristol- Myers Squibb Company, Eli Lilly and Company, Johnson & Johnson Services Inc, Kyowa Kirin Co, Merck & Co, Novartis International AG, Pfizer Inc, Takeda Pharmaceutical Company, USB S.A, FunPep Co Ltd, and other prominent players. The players maintain their dominance in the market by investing in research and development activities, integrating the latest and advanced technologies into their products, and launching improved products for the customers.

Don’t miss the business opportunity of the global axial spondyloarthritis market. Consult our analysts to gain crucial insights and facilitate your business growth.

The report's in-depth analysis provides information about growth potential, upcoming trends, and the global axial spondyloarthritis market statistics. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in the global axial spondyloarthritis market ¬along with industry insights to help decision-makers make sound strategic decisions. Furthermore, the report also analyses the market's growth drivers, challenges, and competitive dynamics.


This product will be delivered within 2 business days.

Table of Contents

1. Research Framework
1.1. Research Objective
1.2. Product Overview
1.3. Market Segmentation
2. Research Methodology
2.1. Qualitative Research
2.1.1. Primary & Secondary Research
2.2. Quantitative Research
2.3. Market Breakdown & Data Triangulation
2.3.1. Secondary Research
2.3.2. Primary Research
2.4. Breakdown of Primary Research Respondents, By Region
2.5. Assumption & Limitation
3. Executive Summary
4. Global Axial Spondyloarthritis Market Insights
4.1. Industry Value Chain Analysis
4.2. DROC Analysis
4.2.1. Growth Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.2.4. Challenges
4.3. Technological Advancement/Recent Development
4.4. Regulatory Framework
4.5. Porter’s Five Forces Analysis
4.5.1. Bargaining Power of Suppliers
4.5.2. Bargaining Power of Buyers
4.5.3. Threat of New Entrants
4.5.4. Threat of Substitutes
4.5.5. Intensity of Rivalry
5. Global Axial Spondyloarthritis Market Overview
5.1. Market Size & Forecast by Value, 2018-2028
5.1.1. By Value (USD Million)
5.2. Market Share & Forecast
5.2.1. By Commercialized Therapies
5.2.1.1. Anti-tumor Necrosis Factor Therapy (TNF)
5.2.1.2. Anti-Interleukin Therapy (IL)
5.2.1.3. Anti-Janus Kinase Therapy (JAK)
5.2.2. By Potential Pipeline Products
5.2.2.1. Anti-Janus Kinase Therapy (JAK)
5.2.2.2. Anti-Interleukin (IL)-17 Therapy
5.2.2.3. Other
5.2.3. By Indication
5.2.3.1. Ankylosing Spondylitis
5.2.3.2. Non-Radiographic Axial Spondylitis
5.2.4. By Region
5.2.4.1. North America
5.2.4.2. Europe
5.2.4.3. The Asia Pacific
5.2.4.4. Latin America
5.2.4.5. The Middle East and Africa
6. North America Axial Spondyloarthritis Market
6.1. Market Size & Forecast by Value, 2018-2028
6.1.1. By Value (USD Million)
6.2. Market Share & Forecast
6.2.1. By Commercialized Therapies
6.2.2. By Potential Pipeline Products
6.2.3. By Indication
6.2.4. By Country
6.2.4.1. United States
6.2.4.2. Canada
7. Europe Axial Spondyloarthritis Market
7.1. Market Size & Forecast by Value, 2018-2028
7.1.1. By Value (USD Million)
7.2. Market Share & Forecast
7.2.1. By Commercialized Therapies
7.2.2. By Potential Pipeline Products
7.2.3. By Indication
7.2.4. By Country
7.2.4.1. Germany
7.2.4.2. United Kingdom
7.2.4.3. Italy
7.2.4.4. France
7.2.4.5. Spain
7.2.4.6. Rest of Europe
8. The Asia Pacific Axial Spondyloarthritis Market
8.1. Market Size & Forecast by Value, 2018-2028
8.1.1. By Value (USD Million)
8.2. Market Share & Forecast
8.2.1. By Commercialized Therapies
8.2.2. By Potential Pipeline Products
8.2.3. By Indication
8.2.4. By Country
8.2.4.1. China
8.2.4.2. India
8.2.4.3. Japan
8.2.4.4. South Korea
8.2.4.5. Rest of Asia Pacific
9. Latin America Axial Spondyloarthritis Market
9.1. Market Size & Forecast by Value, 2018-2028
9.1.1. By Value (USD Million)
9.2. Market Share & Forecast
9.2.1. By Commercialized Therapies
9.2.2. By Potential Pipeline Products
9.2.3. By Indication
9.2.4. By Country
9.2.4.1. Brazil
9.2.4.2. Mexico
9.2.4.3. Rest of Latin America
10. The Middle East & Africa Axial Spondyloarthritis Market
10.1. Market Size & Forecast by Value, 2018-2028
10.1.1. By Value (USD Million)
10.2. Market Share & Forecast
10.2.1. By Commercialized Therapies
10.2.2. By Potential Pipeline Products
10.2.3. By Indication
10.2.4. By Country
10.2.4.1. Brazil
10.2.4.2. Mexico
10.2.4.3. Rest of Latin America
11. Competitive Landscape
11.1. List of Key Players and Their Offerings
11.2. Market Share Analysis, 2021
11.3. Competitive Benchmarking, By Operating Parameters
11.4. Key Strategic Development (Merger, Acquisition, Partnership.)
12. Impact of Covid-19 on Global Biomass Briquettes Industry
13. Company Profile (Company Overview, Financial Matrix, Competitive landscape, Key Personnel, Key Competitors, Contact Address, and Strategic Outlook)
13.1. AbbVie Inc.
13.2. Amgen Inc.
13.3. Bristol-Myers Sqiubb Company
13.4. Eli Lilly and Company
13.5. Johnson & Johnson Services Inc.
13.6. Kyowa kirin Co
13.7. Merck & co
13.8. Novartis International AG
13.9. Pfizer Inc
13.10. Takeda Pharmaceutical Company
13.11. USB S.A
13.12. FunPep Co., Ltd
14. Key Strategic Recommendations
List Of Figures
Figure 1: Global Axial Spondyloarthritis Market Segmentation
Figure 2: Global Axial Spondyloarthritis Industry Value Chain Analysis
Figure 3: Global Axial Spondyloarthritis Market Size, By Value (USD Million), 2018-2028
Figure 4: Global Axial Spondyloarthritis Market Share (%), By Commercialized Therapies, By Value, 2018-2028
Figure 5: Global Axial Spondyloarthritis Market Share (%), By Potential Pipeline Products, By Value, 2018-2028
Figure 6: Global Axial Spondyloarthritis Market Share (%), By Indication, By Value, 2018-2028
Figure 7: Global Axial Spondyloarthritis Market Share (%), By Country, By Value, 2018-2028
Figure 8: North America Axial Spondyloarthritis Market Size, By Value (USD Million), 2018-2028
Figure 9: North America Axial Spondyloarthritis Market Share (%), By Commercialized Therapies, By Value, 2018-2028
Figure 10: North America Axial Spondyloarthritis Market Share (%), By Potential Pipeline Products, By Value, 2018-2028
Figure 11: North America Axial Spondyloarthritis Market Share (%), By Indication, By Value, 2018-2028
Figure 12: North America Axial Spondyloarthritis Market Share (%), By Country, By Value, 2018-2028
Figure 13: Europe Axial Spondyloarthritis Market Size, By Value (USD Million), 2018-2028
Figure 14: Europe Axial Spondyloarthritis Market Share (%), By Commercialized Therapies, By Value, 2018-2028
Figure 15: Europe Axial Spondyloarthritis Market Share (%), By Potential Pipeline Products, By Value, 2018-2028
Figure 16: Europe Axial Spondyloarthritis Market Share (%), By Indication, By Value, 2018-2028
Figure 17: Europe Axial Spondyloarthritis Market Share (%), By Country, By Value, 2018-2028
Figure 18: The Asia-Pacific Axial Spondyloarthritis Market Size, By Value (USD Million), 2018-2028
Figure 19: The Asia-Pacific Axial Spondyloarthritis Market Share (%), By Commercialized Therapies, By Value, 2018-2028
Figure 20: The Asia-Pacific Axial Spondyloarthritis Market Share (%), By Potential Pipeline Products, By Value, 2018-2028
Figure 21: The Asia-Pacific Axial Spondyloarthritis Market Share (%), By Indication, By Value, 2018-2028
Figure 22: The Asia-Pacific Axial Spondyloarthritis Market Share (%), By Country, By Value, 2018-2028
Figure 23: Latin America Axial Spondyloarthritis Market Size, By Value (USD Million), 2018-2028
Figure 24: Latin America Axial Spondyloarthritis Market Share (%), By Commercialized Therapies, By Value, 2018-2028
Figure 25: Latin America Axial Spondyloarthritis Market Share (%), By Potential Pipeline Products, By Value, 2018-2028
Figure 26: Latin America Axial Spondyloarthritis Market Share (%), By Indication, By Value, 2018-2028
Figure 27: Latin America Axial Spondyloarthritis Market Share (%), By Country, By Value, 2018-2028
Figure 28: The Middle East & Africa Axial Spondyloarthritis Market Size, By Value (USD Million), 2018-2028
Figure 29: The Middle East & Africa Axial Spondyloarthritis Market Share (%), By Commercialized Therapies, By Value, 2018-2028
Figure 30: The Middle East & Africa Axial Spondyloarthritis Market Share (%), By Potential Pipeline Products, By Value, 2018-2028
Figure 31: The Middle East & Africa Axial Spondyloarthritis Market Share (%), By Indication, By Value, 2018-2028
Figure 32: The Middle East & Africa Axial Spondyloarthritis Market Share (%), By Country, By Value, 2018-2028
Figure 33: Global Axial Spondyloarthritis Market Share Analysis, 2021
List Of Tables
Table 1: Global Axial Spondyloarthritis Market Size, By Commercialized Therapies, By Value (USD Million), 2018-2028
Table 2: Global Axial Spondyloarthritis Market Size, By Potential Pipeline Products, By Value (USD Million), 2018-2028
Table 3: Global Axial Spondyloarthritis Market Size, By Indication, By Value (USD Million), 2018-2028
Table 4: Global Axial Spondyloarthritis Market Size. By Country, By Value (USD Million), 2018-2028
Table 5: North America Axial Spondyloarthritis Market Size, By Commercialized Therapies, By Value (USD Million), 2018-2028
Table 6: North America Axial Spondyloarthritis Market Size, By Potential Pipeline Products, By Value (USD Million), 2018-2028
Table 7: 28 North America Axial Spondyloarthritis Market Size (USD Million), By Indication, By Value 2018-2028
Table 8: 28 North America Axial Spondyloarthritis Market Size (USD Million), By Country, By Value 2018-2028
Table 9: Europe Axial Spondyloarthritis Market Size, By Commercialized Therapies, By Value (USD Million), 2018-2028
Table 10: Europe Axial Spondyloarthritis Market Size, By Potential Pipeline Products, By Value (USD Million), 2018-2028
Table 11: 40 Europe Axial Spondyloarthritis Market Size (USD Million), By Indication, By Value 2018-2028
Table 12: 40 Europe Axial Spondyloarthritis Market Size (USD Million), By Country, By Value 2018-2028
Table 13: The Asia-Pacific Axial Spondyloarthritis Market Size, By Commercialized Therapies, By Value (USD Million), 2018-2028
Table 14: The Asia-Pacific Axial Spondyloarthritis Market Size, By Potential Pipeline Products, By Value (USD Million), 2018-2028
Table 15: The Asia-Pacific Axial Spondyloarthritis Market Size (USD Million), By Indication, By Value 2018-2028
Table 16: The Asia-Pacific Axial Spondyloarthritis Market Size (USD Million), By Country, By Value 2018-2028
Table 17: Latin America Axial Spondyloarthritis Market Size, By Commercialized Therapies, By Value (USD Million), 2018-2028
Table 18: Latin America Axial Spondyloarthritis Market Size, By Potential Pipeline Products, By Value (USD Million), 2018-2028
Table 19: Latin America Axial Spondyloarthritis Market Size (USD Million), By Indication, By Value 2018-2028
Table 20: Latin America Axial Spondyloarthritis Market Size (USD Million), By Country, By Value 2018-2028
Table 21: The Middle East & Africa Axial Spondyloarthritis Market Size, By Commercialized Therapies, By Value (USD Million), 2018-2028
Table 22: The Middle East & Africa Axial Spondyloarthritis Market Size, By Potential Pipeline Products, By Value (USD Million), 2018-2028
Table 23: The Middle East & Africa Axial Spondyloarthritis Market Size (USD Million), By Indication, By Value 2018-2028
Table 24: The Middle East & Africa Axial Spondyloarthritis Market Size (USD Million), By Country, By Value 2018-2028
Table 25: List of Key Players and Their Offerings
Table 26: Competitive Benchmarking, by Operating Parameters
Table 27 AbbVie Inc. Company Overview
Table 28 AbbVie Inc. Financial Overview
Table 29 Amgen Inc. Company Overview
Table 30 Amgen Inc. Financial Overview
Table 31 Bristol-Myers Sqiubb Company Overview
Table 32 Bristol-Myers Sqiubb Company Financial Overview
Table 33 Eli Lilly and Company Overview
Table 34 Eli Lilly and Company Financial Overview
Table 35 Johnson & Johnson Services Inc. Company Overview
Table 36 Johnson & Johnson Services Inc. Financial Overview
Table 37 Kyowa kirin Co Company Overview
Table 38 Kyowa kirin Co Financial Overview
Table 39 Merck & co Company Overview
Table 40 Merck & co Financial Overview
Table 41 Novartis International AG Company Overview
Table 42 Novartis International AG Financial Overview
Table 43 Pfizer Inc. Company Overview
Table 44 Pfizer Inc. Financial Overview
Table 45 Takeda Pharmaceutical Company Overview
Table 46 Takeda Pharmaceutical Company Financial Overview
Table 47 USB S.A Company Overview
Table 48 USB S.A Financial Overview
Table 49 FunPep Co., Ltd Company Overview
Table 50 FunPep Co., Ltd Financial Overview

Methodology

Loading
LOADING...